Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revised Tafenoquine Dose for Vivax Malaria
NCT06148792Phase 3Recruiting
- Sponsor
- Menzies School of Health Research
- Start
- May 2024
- Primary completion
- Mar 2027
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of tafenoquine in Plasmodium vivax malaria (3 arms), sponsored by Menzies School of Health Research. Primary endpoint: Incidence risk of vivax parasitaemia at 4 months. Started May 2024; status: recruiting.
02
Drugs
tafenoquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT06148792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06148792.